27:
1261:
308:
technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies,
559:
On March 2, 2023, MorphoSys announced that the company would end its preclinical research programs and cease all related activities. According to the press release, this step is justified by challenges in the pharmaceutical market, which are forcing the company to optimize its cost structure and to
952:
483:
On July 31, 2020, Monjuvi (tafasitamab-cxix) was approved by the U.S. FDA in combination with lenalidomide for the medical treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who
847:
578:
Another technology recently developed is the OkapY bispecific antibody technology. MorphoSys’ OkapY technology is a new proprietary “2+1” bispecific antibody format with the hysicochemical properties to simplify the development and large-scale production of such molecules.
749:
973:
910:
507:
As of
December 2020, MorphoSys had 116 drug candidates which are developed by MorphoSys and other pharmaceutical companies, 28 of which were in clinical development. Two antibodies developed by MorphoSys are already approved and marketed.
931:
868:
468:
Corporation signed a collaboration and license agreement for the global development and commercialization of tafasitamab. On March 3, 2020, the agreement received antitrust clearance and thus became effective.
498:
agreed to acquire
Morphosys for €2.7 billion. In June 2024, Morphosys announced its intention to delist from the Frankfurt Stock Exchange and merge into Novartis. The merger was approved in August 2024.
1099:
848:"MorphoSys Announces Closing of Nasdaq IPO through an ADS Offering and Exercise of the Underwriters' Option to Purchase Additional ADSs, Leading to Total Gross Proceeds of USD 239 million"
889:
974:"FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)"
994:
953:"FDA Accepts MorphoSys' Biologics License Application (BLA) and Grants Priority Review for Tafasitamab and Lenalidomide for the Treatment of Relapsed/Refractory DLBCL"
1470:
347:
entered into a strategic partnership for the research and development of biopharmaceuticals, which was expanded in 2007. Additional discovery partnerships included:
571:
MorphoSys’ main technology is HuCAL (Human
Combinatorial Antibody Library), which is a collection of more than ten billion fully human antibodies in the form of a
1035:"MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys' Minority Shareholders – Company Announcement - FT.com"
911:"MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab"
725:
770:
1058:
1450:
1169:
1016:
792:"MorphoSys' licensee Janssen receives Japanese approval for Tremfya to treat moderate to severe forms of psoriasis & psoriatic arthritis"
684:
1480:
1445:
1034:
826:
1250:
1134:
491:
In June 2021, Morphosys announced its acquisition of clinical stage biotechnology company
Constellation Pharma for US$ 1.7 billion.
1475:
1455:
750:"MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis"
340:
The company was founded in 1992. In 1999, MorphoSys listed on the
Frankfurt Stock Exchange under the ticker symbol "MOR".
382:
for otilimab. In 2019, GlaxoSmithKline initiated a phase 3 clinical development program with otilimab (now GSK3196165).
814:
186:
665:
519:. Tafasitamab is being evaluated in several clinical trials, alone and in combination with other anti-cancer drugs.
461:. The submission was accepted for filing in February 2020, and a decision on the filing is expected in August 2020.
1460:
932:"MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab"
485:
1465:
1243:
477:
1085:
473:
458:
450:
701:
869:"MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA"
1154:
428:
1228:
1236:
726:"MorphoSys Signs Global License Agreement with GlaxoSmithKline for Anti-Inflammatory Program MOR103"
321:
146:
54:
1208:
439:
542:. Felzartamab (MOR202/TJ202) is currently under investigation by I-Mab in three clinical trials.
424:
138:
132:
1059:"Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting"
527:
374:(now otilimab) entered clinical development. Following the publication of promising results in
568:
MorphoSys has discovered a number of antibody technologies that are use for drug development.
1344:
1314:
791:
771:"MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program"
1409:
1399:
554:
534:
affecting the kidneys. In 2017, MorphoSys entered into a regional licensing agreement with
413:
375:
8:
516:
314:
1309:
995:"FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma"
560:
focus all resources more on oncology products in the mid to late stage of development.
531:
397:
352:
277:
156:
67:
58:
1324:
1319:
1279:
545:
Otilimab (MOR103/GSK3196165) is a fully human monoclonal antibody directed against
417:
231:
1419:
1120:
550:
409:
379:
356:
446:
37:
1017:"MorphoSys Buys Constellation Pharma in $ 1.7B Deal. Is Biotech M&A Back?"
1439:
1414:
572:
539:
167:
85:
45:
1394:
1100:"MorphoSys Signs Regional License Agreement for Antibody MOR202 with I-Mab"
454:
890:"MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S."
511:
Tafasitamab (MOR208) is a humanized monoclonal antibody directed against
390:
360:
522:
Felzartamab (MOR202)is a humanized monoclonal antibody directed against
476:(BLA) for filing and granted priority review for tafasitamab, setting a
1369:
1364:
1334:
1258:
1135:"MorphoSys Stops Work and Operations on Pre-Clinical Research Programs"
827:"Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market"
401:
201:
617:
1404:
1304:
646:
1218:
538:
to develop and commercialize
Felzartamab (called TJ202 by I-Mab) in
535:
1349:
1339:
495:
344:
329:
297:
152:
1260:
553:. Otilimab is currently under investigation in a Phase 3 trial in
1354:
1299:
1289:
1223:
472:
In March 2020, MorphoSys announced that the FDA had accepted the
405:
396:
In July 2017, the first of MorphoSys’ platform drugs received US
305:
301:
285:
114:
26:
289:
1424:
1384:
1379:
1374:
1329:
1284:
1264:
546:
465:
438:
In 2018, the company established a wholly owned US subsidiary,
432:
371:
364:
325:
310:
293:
281:
63:
1294:
416:, was first approved for the treatment of moderate-to-severe
348:
216:
1201:
685:"Novartis to acquire cancer-centric MorphoSys for $ 2.9 bln"
523:
512:
280:
company founded in 1992. The company is headquartered near
143:
Dr. Malte Peters (Chief
Research & Development Officer)
72:
1213:
924:
808:
386:
309:
MorphoSys also has a proprietary pipeline with a focus on
1389:
744:
742:
262:
408:), which was developed and is being commercialized by
739:
453:(BLA) to the FDA for tafasitamab in combination with
420:
in the United States, the
European Union and Canada.
903:
720:
718:
296:, Massachusetts, in the US. The company has various
385:In 2010, MorphoSys signed a license agreement with
370:In 2008, the company’s first proprietary antibody
715:
1471:Companies listed on the Frankfurt Stock Exchange
1437:
332:agreed to acquire the company in February 2024.
1113:
1080:
1078:
1244:
515:in clinical development for the treatment of
435:stock exchange, also under the symbol "MOR."
1014:
378:, MorphoSys signed a license agreement with
1451:Biotechnology companies established in 1992
1127:
1075:
660:
658:
656:
427:in which the company raised $ 239 million,
1251:
1237:
1177:(Speech). J.P. Morgan HealthcareConference
696:
694:
668:. U.S. Securities and Exchange Commission.
641:
639:
637:
635:
575:bank and a system for their optimization.
1167:
612:
526:for the treatment of anti-PLA2R-positive
457:for the treatment of relapsed/refractory
1121:"I-Mab Biopharma's therapeutic pipeline"
653:
610:
608:
606:
604:
602:
600:
598:
596:
594:
592:
691:
632:
1438:
480:(PDUFA) goal date of August 30, 2020.
1232:
1161:
1147:
589:
288:, and has a wholly owned subsidiary,
679:
677:
675:
445:In December 2019, based on positive
13:
1481:Announced mergers and acquisitions
1446:Biotechnology companies of Germany
1171:Engineering theMedicinesofTomorrow
431:of MorphoSys began trading on the
14:
1492:
1193:
1015:Nathan-Kazis, Josh (2021-06-02).
672:
647:"MorphoSys' therapeutic pipeline"
449:results, the company submitted a
1259:
549:. The program is outlicensed to
25:
16:German biopharmaceutical company
1092:
1051:
1027:
1008:
987:
966:
945:
882:
861:
840:
819:
486:autologous stem cell transplant
464:In January 2020, MorphoSys and
320:MorphoSys AG was listed on the
1476:Companies listed on the Nasdaq
1456:1992 establishments in Germany
1168:MorphoSys (January 13, 2021).
815:Guselkumab BLA Approval Letter
784:
763:
702:"otilimab (MOR103/GSK3196165)"
478:Prescription Drug User Fee Act
423:In April 2018, following a US
1:
582:
563:
474:Biologics License Application
459:diffuse large B-cell lymphoma
451:Biologics License Application
7:
502:
97:; 32 years ago
10:
1497:
557:that started in July 2019.
429:American depositary shares
335:
1275:
257:
244:
229:
214:
199:
184:
173:
163:
125:
109:
91:
81:
43:
33:
24:
322:Frankfurt Stock Exchange
1461:Companies in the TecDAX
773:. MorphoSys. 2010-06-27
728:. MorphoSys. 2013-06-03
704:. MorphoSys. 2014-10-27
425:initial public offering
343:In 2004, MorphoSys and
687:. Reuters. 2024-02-05.
528:membranous nephropathy
355:(2000), Centocor (now
1466:Companies in the MDAX
1345:Infineon Technologies
1315:CompuGroup Medical SE
1267:companies of Germany
1102:. dgap.de. 2017-11-30
997:. FDA.gov. 2020-08-03
976:. dgap.de. 2020-08-01
955:. dgap.de. 2020-03-02
934:. dgap.de. 2020-03-03
913:. dgap.de. 2020-01-13
871:. dgap.de. 2019-12-30
850:. dgap.de. 2018-04-24
752:. dgap.de. 2019-07-03
484:are not eligible for
414:Johnson & Johnson
145:Dr. Roland Wandeler (
131:Dr. Jean-Paul Kress (
1410:SMA Solar Technology
1400:Siemens Healthineers
829:. Nasdaq. 2018-04-19
618:"Annual Report 2020"
555:rheumatoid arthritis
376:rheumatoid arthritis
1224:Lanthio Pharma B.V.
892:dgap.de. 2020-01-13
517:B-cell malignancies
315:autoimmune diseases
246:Number of employees
21:
1310:Carl Zeiss Meditec
1269:updated 11.02.2024
1123:. I-Man Biopharma.
532:autoimmune disease
494:In February 2024,
398:marketing approval
19:
1433:
1432:
1295:Atoss Software AG
1280:1&1 Drillisch
1270:
1209:MorphoSys US Inc.
440:MorphoSys US Inc.
290:MorphoSys US Inc.
278:biopharmaceutical
271:
270:
253:
240:
225:
222:€1,659.5 million
210:
195:
180:
157:Supervisory Board
151:Dr. Marc Cluzel (
1488:
1320:Deutsche Telekom
1268:
1263:
1253:
1246:
1239:
1230:
1229:
1205:
1204:
1202:Official website
1187:
1186:
1184:
1182:
1176:
1165:
1159:
1158:
1151:
1145:
1144:
1142:
1141:
1131:
1125:
1124:
1117:
1111:
1110:
1108:
1107:
1096:
1090:
1089:
1082:
1073:
1072:
1070:
1069:
1055:
1049:
1048:
1046:
1045:
1031:
1025:
1024:
1012:
1006:
1005:
1003:
1002:
991:
985:
984:
982:
981:
970:
964:
963:
961:
960:
949:
943:
942:
940:
939:
928:
922:
921:
919:
918:
907:
901:
900:
898:
897:
886:
880:
879:
877:
876:
865:
859:
858:
856:
855:
844:
838:
837:
835:
834:
823:
817:
812:
806:
805:
803:
802:
788:
782:
781:
779:
778:
767:
761:
760:
758:
757:
746:
737:
736:
734:
733:
722:
713:
712:
710:
709:
698:
689:
688:
681:
670:
669:
662:
651:
650:
643:
630:
629:
627:
625:
614:
418:plaque psoriasis
412:a subsidiary of
389:for MOR208 (now
328:stock exchange.
267:
264:
251:
238:
234:
223:
219:
208:
193:
187:Operating income
178:
105:
103:
98:
29:
22:
18:
1496:
1495:
1491:
1490:
1489:
1487:
1486:
1485:
1436:
1435:
1434:
1429:
1420:United Internet
1271:
1257:
1219:I-Mab Biopharma
1200:
1199:
1196:
1191:
1190:
1180:
1178:
1174:
1166:
1162:
1153:
1152:
1148:
1139:
1137:
1133:
1132:
1128:
1119:
1118:
1114:
1105:
1103:
1098:
1097:
1093:
1084:
1083:
1076:
1067:
1065:
1057:
1056:
1052:
1043:
1041:
1033:
1032:
1028:
1013:
1009:
1000:
998:
993:
992:
988:
979:
977:
972:
971:
967:
958:
956:
951:
950:
946:
937:
935:
930:
929:
925:
916:
914:
909:
908:
904:
895:
893:
888:
887:
883:
874:
872:
867:
866:
862:
853:
851:
846:
845:
841:
832:
830:
825:
824:
820:
813:
809:
800:
798:
790:
789:
785:
776:
774:
769:
768:
764:
755:
753:
748:
747:
740:
731:
729:
724:
723:
716:
707:
705:
700:
699:
692:
683:
682:
673:
664:
663:
654:
645:
644:
633:
623:
621:
616:
615:
590:
585:
566:
558:
551:GlaxoSmithKline
536:I-Mab Biopharma
505:
410:Janssen Biotech
380:GlaxoSmithKline
357:Janssen Biotech
338:
261:
247:
237:€621.3 million
230:
215:
204:
189:
177:€327.7 million
150:
144:
142:
136:
128:
121:
117:
101:
99:
96:
77:
48:
17:
12:
11:
5:
1494:
1484:
1483:
1478:
1473:
1468:
1463:
1458:
1453:
1448:
1431:
1430:
1428:
1427:
1422:
1417:
1412:
1407:
1402:
1397:
1392:
1387:
1382:
1377:
1372:
1367:
1362:
1357:
1352:
1347:
1342:
1337:
1332:
1327:
1322:
1317:
1312:
1307:
1302:
1297:
1292:
1287:
1282:
1276:
1273:
1272:
1256:
1255:
1248:
1241:
1233:
1227:
1226:
1221:
1216:
1211:
1206:
1195:
1194:External links
1192:
1189:
1188:
1160:
1146:
1126:
1112:
1091:
1074:
1050:
1039:markets.ft.com
1026:
1007:
986:
965:
944:
923:
902:
881:
860:
839:
818:
807:
783:
762:
738:
714:
690:
671:
652:
631:
587:
586:
584:
581:
565:
562:
504:
501:
447:clinical trial
337:
334:
324:and on the US
269:
268:
259:
255:
254:
248:
245:
242:
241:
235:
227:
226:
220:
212:
211:
207:€97.9 million
205:
200:
197:
196:
192:€27.4 million
190:
185:
182:
181:
175:
171:
170:
165:
161:
160:
129:
126:
123:
122:
119:
113:
111:
107:
106:
93:
89:
88:
83:
79:
78:
76:
75:
73:MDAX Component
70:
61:
51:
49:
44:
41:
40:
35:
31:
30:
15:
9:
6:
4:
3:
2:
1493:
1482:
1479:
1477:
1474:
1472:
1469:
1467:
1464:
1462:
1459:
1457:
1454:
1452:
1449:
1447:
1444:
1443:
1441:
1426:
1423:
1421:
1418:
1416:
1415:TeamViewer AG
1413:
1411:
1408:
1406:
1403:
1401:
1398:
1396:
1393:
1391:
1388:
1386:
1383:
1381:
1378:
1376:
1373:
1371:
1368:
1366:
1363:
1361:
1358:
1356:
1353:
1351:
1348:
1346:
1343:
1341:
1338:
1336:
1333:
1331:
1328:
1326:
1325:Energiekontor
1323:
1321:
1318:
1316:
1313:
1311:
1308:
1306:
1303:
1301:
1298:
1296:
1293:
1291:
1288:
1286:
1283:
1281:
1278:
1277:
1274:
1266:
1262:
1254:
1249:
1247:
1242:
1240:
1235:
1234:
1231:
1225:
1222:
1220:
1217:
1215:
1212:
1210:
1207:
1203:
1198:
1197:
1173:
1172:
1164:
1156:
1150:
1136:
1130:
1122:
1116:
1101:
1095:
1087:
1086:"tafasitamab"
1081:
1079:
1064:
1060:
1054:
1040:
1036:
1030:
1022:
1018:
1011:
996:
990:
975:
969:
954:
948:
933:
927:
912:
906:
891:
885:
870:
864:
849:
843:
828:
822:
816:
811:
797:
796:pharmabiz.com
793:
787:
772:
766:
751:
745:
743:
727:
721:
719:
703:
697:
695:
686:
680:
678:
676:
667:
661:
659:
657:
648:
642:
640:
638:
636:
619:
613:
611:
609:
607:
605:
603:
601:
599:
597:
595:
593:
588:
580:
576:
574:
573:phage display
569:
561:
556:
552:
548:
543:
541:
540:Greater China
537:
533:
529:
525:
520:
518:
514:
509:
500:
497:
492:
489:
487:
481:
479:
475:
470:
467:
462:
460:
456:
452:
448:
443:
441:
436:
434:
430:
426:
421:
419:
415:
411:
407:
403:
399:
394:
392:
388:
383:
381:
377:
373:
368:
366:
362:
358:
354:
350:
346:
341:
333:
331:
327:
323:
318:
316:
312:
307:
303:
299:
295:
291:
287:
283:
279:
275:
266:
260:
256:
249:
243:
236:
233:
228:
221:
218:
213:
206:
203:
198:
191:
188:
183:
176:
172:
169:
168:Immunotherapy
166:
162:
158:
154:
148:
140:
134:
130:
124:
116:
112:
108:
94:
90:
87:
86:Biotechnology
84:
80:
74:
71:
69:
65:
62:
60:
56:
53:
52:
50:
47:
42:
39:
36:
32:
28:
23:
1359:
1179:. Retrieved
1170:
1163:
1157:. MorphoSys.
1149:
1138:. Retrieved
1129:
1115:
1104:. Retrieved
1094:
1088:. MorphoSys.
1066:. Retrieved
1063:Morphosys de
1062:
1053:
1042:. Retrieved
1038:
1029:
1020:
1010:
999:. Retrieved
989:
978:. Retrieved
968:
957:. Retrieved
947:
936:. Retrieved
926:
915:. Retrieved
905:
894:. Retrieved
884:
873:. Retrieved
863:
852:. Retrieved
842:
831:. Retrieved
821:
810:
799:. Retrieved
795:
786:
775:. Retrieved
765:
754:. Retrieved
730:. Retrieved
706:. Retrieved
649:. MorphoSys.
622:. Retrieved
577:
570:
567:
544:
521:
510:
506:
493:
490:
482:
471:
463:
455:lenalidomide
444:
437:
422:
404:(brand name
395:
384:
369:
342:
339:
319:
276:is a German
274:MorphoSys AG
273:
272:
232:Total equity
217:Total assets
110:Headquarters
34:Company type
20:MorphoSys AG
1214:Xencor Inc.
666:"Form 20-F"
620:. MorphoSys
391:tafasitamab
387:Xencor Inc.
363:(2001) and
361:Schering AG
1440:Categories
1370:Nemetschek
1365:Nagarro SE
1140:2023-03-02
1106:2020-04-29
1068:2024-08-28
1044:2024-06-21
1001:2021-04-30
980:2021-04-30
959:2020-04-29
938:2020-04-29
917:2020-04-29
896:2020-04-29
875:2020-04-29
854:2020-04-29
833:2020-04-29
801:2018-06-05
777:2020-04-29
756:2020-04-29
732:2020-04-29
708:2018-06-23
583:References
564:Technology
402:Guselkumab
252:(end 2020)
239:(end 2020)
224:(end 2020)
202:Net income
137:Sung Lee (
127:Key people
1405:Siltronic
1395:Sartorius
1360:MorphoSys
1305:Cancom AG
1181:April 29,
359:, 2000),
263:morphosys
46:Traded as
1350:Jenoptik
1340:Hensoldt
1021:Barron's
624:29 April
503:Pipeline
496:Novartis
488:(ASCT).
367:(2003).
351:(1999),
345:Novartis
330:Novartis
298:antibody
164:Products
153:chairman
82:Industry
1355:Kontron
1335:Freenet
1300:Bechtle
1290:Aixtron
1155:"HuCaL"
406:Tremfya
336:History
306:peptide
302:protein
286:Germany
258:Website
174:Revenue
120:Germany
115:Planegg
100: (
92:Founded
66::
57::
1425:Verbio
1385:Qiagen
1380:PNE AG
1375:Nordex
1330:Evotec
1285:Adtran
1265:TecDAX
547:GM-CSF
466:Incyte
433:Nasdaq
372:MOR103
365:Pfizer
326:Nasdaq
311:cancer
294:Boston
282:Munich
209:(2020)
194:(2020)
179:(2020)
64:Nasdaq
38:Public
1175:(PDF)
530:, an
353:Roche
349:Bayer
292:, in
1183:2021
626:2021
524:CD38
513:CD19
317:.
313:and
304:and
265:.com
250:615
102:1992
95:1992
1390:SAP
393:).
155:of
147:CCO
139:CFO
133:CEO
68:MOR
59:MOR
55:FWB
1442::
1077:^
1061:.
1037:.
1019:.
794:.
741:^
717:^
693:^
674:^
655:^
634:^
591:^
442:.
400:.
300:,
284:,
118:,
1252:e
1245:t
1238:v
1185:.
1143:.
1109:.
1071:.
1047:.
1023:.
1004:.
983:.
962:.
941:.
920:.
899:.
878:.
857:.
836:.
804:.
780:.
759:.
735:.
711:.
628:.
159:)
149:)
141:)
135:)
104:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
